- Phare
 - Validé par KD/KO
 
Anticorps Polyclonal de lapin anti-PHLPP2
PHLPP2 Polyclonal Antibody for WB, IHC, IF/ICC, IP, ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain, rat, souris et plus (1)
Applications
WB, IHC, IF/ICC, IP, ELISA
Conjugaison
Non conjugué
N° de cat : 25244-1-AP
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en WB | cellules HeLa, cellules NIH/3T3 | 
| Résultats positifs en IP | cellules HeLa, | 
| Résultats positifs en IHC | tissu de cancer du côlon humain,  tissu de côlon humain il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.  | 
| Résultats positifs en IF/ICC | cellules HeLa | 
Dilution recommandée
| Application | Dilution | 
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 | 
| Immunoprécipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate | 
| Immunohistochimie (IHC) | IHC : 1:20-1:200 | 
| Immunofluorescence (IF)/ICC | IF/ICC : 1:10-1:100 | 
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Applications publiées
| KD/KO | See 3 publications below | 
| WB | See 15 publications below | 
| IHC | See 5 publications below | 
| IF | See 2 publications below | 
Informations sur le produit
25244-1-AP cible PHLPP2 dans les applications de WB, IHC, IF/ICC, IP, ELISA et montre une réactivité avec des échantillons Humain, rat, souris
| Réactivité | Humain, rat, souris | 
| Réactivité citée | rat, Humain, poisson-zèbre, souris | 
| Hôte / Isotype | Lapin / IgG | 
| Clonalité | Polyclonal | 
| Type | Anticorps | 
| Immunogène | PHLPP2 Protéine recombinante Ag19000 | 
| Nom complet | PH domain and leucine rich repeat protein phosphatase-like | 
| Masse moléculaire calculée | 1323 aa, 147 kDa | 
| Poids moléculaire observé | 147 kDa | 
| Numéro d’acquisition GenBank | BC129927 | 
| Symbole du gène | PHLPPL | 
| Identification du gène (NCBI) | 23035 | 
| Conjugaison | Non conjugué | 
| Forme | Liquide | 
| Méthode de purification | Purification par affinité contre l'antigène | 
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol | 
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. | 
Informations générales
PHLPP2 also named as PHLPPL is a 1323 amino acid protein, which contains 22 LRR repeats, 1 PH domain and 1 PP2C-like domain. Localized to both the nucleus and the cytoplasm, PHLPPL uses manganese as a cofactor and mediates the dephosphorylation of Akt1, thereby playing a role in cell survival and apoptotic regulation. Multiple isoforms of PHLPPL exist due to alternative splicing events.
Protocole
| Product Specific Protocols | |
|---|---|
| WB protocol for PHLPP2 antibody 25244-1-AP | Download protocol | 
| IHC protocol for PHLPP2 antibody 25244-1-AP | Download protocol | 
| IF protocol for PHLPP2 antibody 25244-1-AP | Download protocol | 
| IP protocol for PHLPP2 antibody 25244-1-AP | Download protocol | 
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols | 
Publications
| Species | Application | Title | 
|---|---|---|
Oxid Med Cell Longev Colonic Epithelial PHLPP2 Deficiency Promotes Colonic Epithelial Pyroptosis by Activating the NF-κB Signaling Pathway.
  | ||
Mol Ther Nucleic Acids Tumor-Derived EV-Encapsulated miR-181b-5p Induces Angiogenesis to Foster Tumorigenesis and Metastasis of ESCC. | ||
Oncotarget PHLPP negatively regulates cell motility through inhibition of Akt activity and integrin expression in pancreatic cancer cells.
  | ||
Oncotarget High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma. | ||
FASEB J Role of epigenetic m6 A RNA methylation in vascular development: mettl3 regulates vascular development through PHLPP2/mTOR-AKT signaling. | ||
Front Oncol Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling. | 
Avis
The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.
FH Slavica (Verified Customer) (10-04-2021)  | The antibody worked very well! 
  | 







